Business
Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting
Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"text","content":"Titan real-world prevalence study data reveals that Demodex blepharitis accounts for over two-thirds of all blepharitis cases and is highly prevalent in many commonly seen patient groups New Titan study data analysis showed that current management tools, such as tea tree oil (TTO) and lid wipes, are ineffective at treating Demodex blepharitis Atlas disease impact study showed that Demodex blepharitis is associated with a significant symptomatic and psychosocial burden, negatively affecting daily life in 80% of patients IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, presented data today from two pioneering studies on the prevalence and impact of Demodex blepharitis at the American Academy of Optometry (AAOpt) 2021 Annual Meeting in Boston, MA, the largest optometry meeting in the U.S. The Titan real-world prevalence study data revealed that Demodex blepharitis accounts for over two-thirds (69%) of all blepharitis cases and is present in many commonly seen patient groups. Additionally, new data revealed a high prevalence of collarettes in patient populations using TTO (75%) and lid wipes (57%), indicating that current management tools for this disease are largely ineffective. There are currently no U.S. Food and Drug Administration (FDA) approved therapeutics for Demodex blepharitis. Tarsus’ lead investigational candidate, TP-03 (lotilaner ophthalmic solution, 0.25%), is currently being evaluated in the Saturn-2, Phase 3, pivotal trial for the treatment of Demodex blepharitis. TP-03 was previously evaluated in the Saturn-1, Phase 2b/3, pivotal trial involving 421 patients. Saturn-1 showed that TP-03 cleared the signs of Demodex blepharitis, met all primary and secondary endpoints with no serious treatment-related adverse events and was well-tolerated. Results from the Saturn-2, Phase 3, pivotal trial are anticipated in Q1 of 2022. “Data from the Titan and Atlas studies provide optometrists with important insights into the prevalence and negative impact Demodex blepharitis can have on patients, as well as the limitations of current management tools,” said Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus. “We kn...